1299346-13-6

Basic information

• Product Name: tert-butyl (2-(4-acetamidobenzamido)phenyl)carbamate
• Synonyms: tert-butyl (2-(4-acetamidobenzamido)phenyl)carbamate
• CAS NO: 1299346-13-6
• Molecular Weight: 369.42
• Mol File: 1299346-13-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl (2-(4-acetamidobenzamido)phenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2-(4-acetamidobenzamido)phenyl)carbamate(1299346-13-6)
• EPA Substance Registry System: tert-butyl (2-(4-acetamidobenzamido)phenyl)carbamate(1299346-13-6)

Safety Data

• Hazardous Substances Data: 1299346-13-6(Hazardous Substances Data)

Upstream product

• 146651-75-4 tert–butyl (2–aminophenyl)carbamate 
• 75-36-5 acetyl chloride 
• 54614-93-6 (2-nitro-phenyl)-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 88-74-4 2-nitro-aniline 
• 95-54-5 1,2-diamino-benzene 
• 556-08-1 p-(acetylamino)benzoic acid 

Downstream Products

• 112522-64-2 CI-994 
• 1353653-79-8 4-acetamido-N-(2-aminophenyl)benzamide trifluoroacetate salt 

Relevant articles and documents

PROTAC-mediated degradation of class i histone deacetylase enzymes in corepressor complexes

We have identified a proteolysis targeting chimera (PROTAC) of class I HDACs 1, 2 and 3. The most active degrader consists of a benzamide HDAC inhibitor, an alkyl linker, and the von Hippel-Lindau E3 ligand. Our PROTAC increased histone acetylation levels and compromised colon cancer HCT116 cell viability, establishing a degradation strategy as an alternative to class I HDAC inhibition.

NOVEL SOLID FORMS OF TACEDINALINE

Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.

THE USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS

The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.